Skip to main content
. Author manuscript; available in PMC: 2017 Sep 15.
Published in final edited form as: Cancer Res. 2016 Aug 3;76(18):5455–5466. doi: 10.1158/0008-5472.CAN-15-3384

Figure 2. Enhanced effects of combined MEK and CDK4/6 inhibition in BRAF and NRAS mutant lines in vitro.

Figure 2

A. MTT cell viability assays of WT/WT, BRAF and NRAS mutant lines treated for four days with single agent (trametinib or palbociclib) or a fixed-ratio (1:100) combination (trametinib plus palbociclib) of both compounds (error bars represent SD). B. Calcusyn combination indices at median effective dose (ED50) generated from MTT assays in Figure A. C. Melanoma cells were plated at low density, treated with DMSO, trametinib (10 nM), palbociclib (1 μM) or the combination. After 1 week, cultures were stained with crystal violet.